Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.
Conditions
Pediatric Brain Tumors
Interventions
FET PET/MRI
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
6 Years to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Glioblastoma Multiforme, GBM
Interventions
18F-FET
Drug
Lead sponsor
Marcelo F. Di Carli, MD, FACC
Other
Eligibility
18 Years to 85 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
High Grade Glioma
Interventions
O-(2-[18F]Fluoroethyl)-L-tyrosine, [18F]-FET with PET/MRI
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
10 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Pituitary Adenoma
Interventions
FET-PET/MRI
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Glioma
Interventions
FET F-18, O-15 Radioisotope, CT scan, MRI with gadolinium-based contrast, Biopsy Collection
Drug · Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Glioma
Interventions
[18F]FMISO-PET with contrast-enhanced MRI
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Intracranial Neoplasm, Low Grade Glioma, Recurrent Glioblastoma, Recurrent World Health Organization (WHO) Grade II Glioma, Recurrent WHO Grade III Glioma
Interventions
F-18 Fluoroethyltyrosine (FET), Positron Emission Tomography (PET)
Drug · Procedure
Lead sponsor
Thomas Hope
Other
Eligibility
3 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
San Francisco, California
Conditions
Glioblastoma, IDH-Wildtype
Interventions
Biospecimen Collection, Computed Tomography, F-18 Fluoroethyltyrosine, Fluorodopa F 18, Magnetic Resonance Imaging, Dose-intensified Photon Beam Radiation Therapy, Standard Photon Beam Radiation Therapy, Dose-intensified Accelerated Photon Beam Radiation Therapy, Accelerated Photon Beam Radiation Therapy, Positron Emission Tomography, Proton Beam Radiation Therapy, Questionnaire Administration, Temozolomide
Procedure · Radiation · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 4 more
Conditions
Retrospective Study, Glioma, Brain Neoplasms
Interventions
18F(FET)PET
Diagnostic Test
Lead sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Industry
Eligibility
Not listed
Enrollment
253 participants
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
No Longer Available No phase listed Expanded access

18F-Floretyrosine Expanded Access Program

NCT06743100
Conditions
Glioma (Any Grade) in the Brain
Interventions
18F-Floretyrosine
Diagnostic Test
Lead sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Industry
Eligibility
3 Years and older
U.S. locations
10
States / cities
Orange, California • Aurora, Colorado • Chicago, Illinois + 6 more